TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12518494

Group type: EXPERIMENTAL
Intervention: Discus Dental Zoom! Chairside System (25% hydrogen peroxide whitening gel)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Opalescence Xtra Boost Kit (38% hydrogen peroxide whitening gel)
Number of subjects: 22
Study: 9811286

Group type: EXPERIMENTAL
Intervention: Garlic extract (Kwai, 300 mg, 3 times a day)
Number of subjects: 30
Study: 7815239

Group type: EXPERIMENTAL
Intervention: Enteral feeding with a whole protein‐based formula (Nutrison Standard, Nutricia)
Number of subjects: 19

Group type: COMPARATOR
Intervention: High‐dose corticosteroids
Number of subjects: 19
Study: 2576361

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride 2 mg/d
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride 4 mg/d
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride with 0.5% blood alcohol concentration
Number of subjects: 48
Study: 778344

Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 42
Study: 29570574

Group type: EXPERIMENTAL
Intervention: PJT-B (Plyometric Jump Training Before Soccer Training)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PJT-A (Plyometric Jump Training After Soccer Training)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study: 29273455

Group type: EXPERIMENTAL
Intervention: Facebook use
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sitting quietly with the option of reading electronic magazines (Control)
Number of subjects: 104
Study: 27881709

Group type: EXPERIMENTAL
Intervention: Metformin use in patients with diabetes mellitus (n = 115)
Number of subjects: 1958

Group type: COMPARATOR
Intervention: Non-users of metformin (DM patients without metformin use and non-DM patients)
Number of subjects: 1958
Study: 24351803

Group type: EXPERIMENTAL
Intervention: Apnea hypopnea index (AHI)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI)
Number of subjects: 298
Study: 22982906

Group type: EXPERIMENTAL
Intervention: Patient counseling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 50
Study: 20163275

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1 to 3 mg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 0
Study: 16450820

Group type: EXPERIMENTAL
Intervention: Plastic wrap fixation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze bandage fixation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adhesive bandage fixation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coban wrap fixation method
Number of subjects: 0
Study: 12604873

Group type: EXPERIMENTAL
Intervention: Walking exercise training program (group W, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (group C, n=15)
Number of subjects: 30
Study: 10985319

Group type: EXPERIMENTAL
Intervention: Multimodal social marketing intervention
Number of subjects: 1402
Study: 8626365

Group type: EXPERIMENTAL
Intervention: Nefazodone, 100 mg b.i.d. starting dose, adjusted to 300-500 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study: 1425394

Group type: EXPERIMENTAL
Intervention: 15 g dextrose
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2866168

Group type: EXPERIMENTAL
Intervention: Sinemet (L-DOPA plus carbidopa) with haloperidol
Number of subjects: 1

Group type: COMPARATOR
Intervention: Haloperidol-placebo
Number of subjects: 1
Study: 29025085

Group type: EXPERIMENTAL
Intervention: 0.2 mg sublingual buprenorphine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 27117531

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg Q3W
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q3W
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q2W
Number of subjects: 449
Study: 24342689

Group type: EXPERIMENTAL
Intervention: Palmitic acid (PA; 2% of diet dry matter)
Number of subjects: 32
Study: 22719063

Group type: EXPERIMENTAL
Intervention: Vdrive robotic system for remote navigation of circular mapping catheters
Number of subjects: 94
Study: 20617288

Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE-inhibitor) for 6 months
Number of subjects: 100
Study: 17852925

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) 4 mg daily
Number of subjects: 20
Study: 15832628

Group type: EXPERIMENTAL
Intervention: Similarity-guided retrieval procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foil memory test procedure
Number of subjects: 0
Study: 12450890

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (5 x 10(7) colony-forming units/mL) in a rose-hip drink, 400 mL/d for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (rose-hip drink without bacteria), 400 mL/d for 6 weeks
Number of subjects: 36
Study: 10496829

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (one interview)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Intensive motivational interviewing (six interviews over 12 weeks)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Financial incentive (30 vouchers for leisure facilities) with intensive motivational interviewing
Number of subjects: 523

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Intervention group (all combined interventions)
Number of subjects: 523
Study: 8630585

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 17.8 ± 2.7 ppm
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (PGI2) at 7.5 ± 2.5 ng/kg min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (PGI2)
Number of subjects: 16
Study: 1746300

Group type: EXPERIMENTAL
Intervention: Physician-administered genogram (PAGE)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Self-administered genogram (SAGE)
Number of subjects: 189

Group type: COMPARATOR
Intervention: No genogram (Control)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Baseline group (without genograms)
Number of subjects: 189
Study: 6121579

Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31023281

Group type: EXPERIMENTAL
Intervention: Immediate PrEP
Number of subjects: 436
Study: 27875076

Group type: EXPERIMENTAL
Intervention: Parental resource empowerment score (mean 2.95, SD 0.56; range 1-4)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Parental resource empowerment score
Number of subjects: 721
Study: 26219141

Group type: EXPERIMENTAL
Intervention: Modified Slow Maxillary Expansion Appliance (MSMEA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 24411524

Group type: EXPERIMENTAL
Intervention: Dual-hemisphere tDCS (anodal over left S1, cathodal over right S1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Uni-hemisphere tDCS (anodal over left S1, cathodal over contralateral supraorbital front)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham tDCS (1mA, 30s)
Number of subjects: 9
Study: 23051949

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study: 19678927

Group type: EXPERIMENTAL
Intervention: Breast Conservative Therapy (BCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 100
Study: 17181851

Group type: EXPERIMENTAL
Intervention: Dietary advice (Advice Group)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control Group (no dietary advice)
Number of subjects: 183
Study: 15880962

Group type: EXPERIMENTAL
Intervention: Xylitol (X group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Sorbitol (G group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: No gum (C group)
Number of subjects: 123
Study: 12458352

Group type: EXPERIMENTAL
Intervention: Zanamivir or oseltamivir
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (before neuraminidase inhibitors)
Number of subjects: 56
Study: 9792309

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome, 5 mg/kg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (AmB, 1 mg/kg/d)
Number of subjects: 66
Study: 10513074

Group type: EXPERIMENTAL
Intervention: Dobutamine at 5 micrograms/Kg/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amrinone at 5 micrograms/Kg/min
Number of subjects: 14
Study: 1675649

Group type: EXPERIMENTAL
Intervention: Emulsion cleansing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Liquid soap
Number of subjects: 38
Study: 6330425

Group type: EXPERIMENTAL
Intervention: Zinc therapy using a nonproprietary zinc dialysate
Number of subjects: 12
Study: 30957382

Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM)
Number of subjects: 163
Study: 26796396

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Low RWT (<0.24)
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Decrease in RWT
Number of subjects: 1260
Study: 25245767

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (IVL) - 2% intravenously (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine analgesia (LEA) - lidocaine epidurally (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group - normal saline (NS) both intravenously and epidurally
Number of subjects: 60
Study: 22234019

Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine (0.1 mg/kg as a preincisional bolus followed by a continuous infusion of 0.05 mg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study: 19661813

Group type: EXPERIMENTAL
Intervention: EEG spectral power during sleep in GERD patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Conventional sleep stage summaries
Number of subjects: 17
Study: 17414140

Group type: EXPERIMENTAL
Intervention: Anoplasty for perineal fistula
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study: 15895327

Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (n=85, 79 completed outcome assessment)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (n=86, 78 completed outcome assessment)
Number of subjects: 171
Study: 11903374

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal surgery (Control)
Number of subjects: 0
Study: 9613405

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg administered the evening and morning before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8512909

Group type: EXPERIMENTAL
Intervention: Intramuscular and oral ketorolac
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3450519

Group type: EXPERIMENTAL
Intervention: Nifedipine therapy for 2 and 14-16 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 42
Study: 29467138

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (provider education, patient decision aid and navigation support)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (consultation and referral, if requested)
Number of subjects: 100
Study: 28002347

Group type: EXPERIMENTAL
Intervention: Airtraq DL videolaryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: McGrath Series 5 videolaryngoscope
Number of subjects: 90
Study: 25491116

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.05% desonide cream
Number of subjects: 0
Study: 22732367

Group type: EXPERIMENTAL
Intervention: Biodegradable interference screw only (group I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biodegradable interference screw supplemented by a post-tie using a washer screw (group II)
Number of subjects: 80
Study: 20507651

Group type: EXPERIMENTAL
Intervention: Higher-pressure/variable-frequency HFCWC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lower-pressure/mid-frequency HFCWC
Number of subjects: 16
Study: 18257177

Group type: EXPERIMENTAL
Intervention: Acupuncture (Hegu (LI 4) and Taichong (LR 3))
Number of subjects: 440

Group type: COMPARATOR
Intervention: Prozac (20 mg/d)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Non-acupoint needling
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440

Group type: COMPARATOR
Intervention: Prozac
Number of subjects: 440
Study: 15678251

Group type: EXPERIMENTAL
Intervention: Topical liposomal heparin spraygel (LHSG) (Lipohep Forte Spraygel, 4 puffs of 458 IU tid, n = 22)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) (Clexane 40 mg once a day, n = 24)
Number of subjects: 46
Study: 12790214

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg + neostigmine 25 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg + neostigmine 50 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 10 mg + dextrose 5%, 1 mL, total volume 3 mL (Group 1)
Number of subjects: 45
Study: 10376255

Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate in gel-forming solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8704690

Group type: EXPERIMENTAL
Intervention: Immunomagnetic CD4+ and CD8+ cell depletion with cyclosporine as GVHD prophylaxis
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cyclosporine as GVHD prophylaxis
Number of subjects: 15
Study: 10895735

Group type: EXPERIMENTAL
Intervention: Saliva substitutes
Number of subjects: 0
Study: 3900727

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (400 mg)
Number of subjects: 6024

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 6024
Study: 31050785

Group type: EXPERIMENTAL
Intervention: Women identifying as refugees
Number of subjects: 1335

Group type: EXPERIMENTAL
Intervention: Women from other conflict-affected backgrounds
Number of subjects: 1335

Group type: EXPERIMENTAL
Intervention: Women born in the host nation
Number of subjects: 1335
Study: 29995724

Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vulvar LSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vulvar HSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vaginal LSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vaginal HSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Cervical lesions in females with vulvar lesions
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Cervical lesions in females with vaginal lesions
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Cervical lesions in females with vaginal or vulvar lesions
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vulvar LSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vulvar HSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vaginal LSILs
Number of subjects: 8798

Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vaginal HSILs
Number of subjects: 8798
Study: 26716580

Group type: EXPERIMENTAL
Intervention: LEV XR 2000 mg/day (mean daily dose 2131 mg/day)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: LEV XR monotherapy
Number of subjects: 190
Study: 23764865

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation plus pressure support ventilation (SIMV-PSV)
Number of subjects: 366
Study: 23008301

Group type: EXPERIMENTAL
Intervention: Short-course (SC) radiotherapy: 5 × 5 Gy in 1 week, early surgery, and six courses of adjuvant chemotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Long-course (LC) chemoradiation: 50.4 Gy, 1.8 Gy/fraction, in 5.5 weeks, with continuous infusional fluorouracil 225 mg/m(2) per day, surgery in 4 to 6 weeks, and four courses of chemotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Short-course (SC) radiotherapy
Number of subjects: 326

Group type: COMPARATOR
Intervention: Long-course (LC) chemoradiation
Number of subjects: 326
Study: 19859670

Group type: EXPERIMENTAL
Intervention: Advanced Standard Treatment (AST) - rheological therapy complemented by distraction and relaxation training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard Treatment (ST) - rheological therapy
Number of subjects: 29
Study: 17931375

Group type: EXPERIMENTAL
Intervention: 10 seconds injection duration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 seconds injection duration
Number of subjects: 50
Study: 15950671

Group type: EXPERIMENTAL
Intervention: Extended transdermal contraception (ORTHO EVRA) used in an extended regimen (84 days)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Traditional 28-day cyclic regimen
Number of subjects: 239
Study: 15046711

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 50 mg/m2
Number of subjects: 14

Group type: COMPARATOR
Intervention: Doxorubicin 50 mg/m2 (first dose only)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin 50 mg/m2 (subsequent cycles)
Number of subjects: 14
Study: 10434821

Group type: EXPERIMENTAL
Intervention: Acupressure at the P6 point
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 7572056

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AED) treatment (carbamazepine, oxcarbazepine, sodium‐valproate, phenobarbital, phenytoin)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Withdrawal of AED monotherapy (carbamazepine or sodium‐valproate)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Switch from phenytoin to carbamazepine monotherapy
Number of subjects: 87
Study: 2338113

Group type: EXPERIMENTAL
Intervention: Renzapride 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renzapride 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renzapride 0.2 to 5 mg
Number of subjects: 0
Study: 320930

Group type: EXPERIMENTAL
Intervention: Methyltestosterone (10 mg daily in linguet form)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Methyltestosterone
Number of subjects: 4
Study: 30535714

Group type: EXPERIMENTAL
Intervention: Submucosal autologous platelet-rich plasma injection (PRP injection group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Submucosal normal saline injection (control group)
Number of subjects: 87
Study: 28486595

Group type: EXPERIMENTAL
Intervention: 100 μg ITM
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 200 μg ITM
Number of subjects: 120

Group type: COMPARATOR
Intervention: Choice of ITM dose (either 100 or 200 μg)
Number of subjects: 120
Study: 25599302

Group type: EXPERIMENTAL
Intervention: Active tDCS (2‐mA anodal tDCS for 5 consecutive 20‐minute sessions)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 48
Study: 23009581

Group type: EXPERIMENTAL
Intervention: PVP combined with (125)I seeds implantation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular radiation therapy
Number of subjects: 50
Study: 20834105

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 16

Group type: COMPARATOR
Intervention: FTC
Number of subjects: 16
Study: 17982752

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (NAC 600 mg and vitamins-minerals)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no adjunctive medical therapy)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 42
Study: 16722854

Group type: EXPERIMENTAL
Intervention: Contreet Foam
Number of subjects: 129

Group type: COMPARATOR
Intervention: Allevyn Hydrocellular
Number of subjects: 129
Study: 12950526

Group type: EXPERIMENTAL
Intervention: d,l‐sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d‐sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dofetilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: azimilide
Number of subjects: 0
Study: 10392481

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 54
Study: 8912765

Group type: COMPARATOR
Intervention: Rifampicin (RMP) 600 mg/d
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT) 300 mg/d
Number of subjects: 298

Group type: COMPARATOR
Intervention: Rifampicin (RMP)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Rifabutin (RBT)
Number of subjects: 298
Study: 1652386

Group type: EXPERIMENTAL
Intervention: Intravenous and subcutaneous salmon calcitonin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7046707

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0
Study: 31740551

Group type: EXPERIMENTAL
Intervention: Capecitabine plus temozolomide (arm A, CAPTEM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: FOLFIRI (arm B)
Number of subjects: 86